US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6098584A
(ja)
|
1983-11-02 |
1985-06-01 |
Canon Inc |
カメラ―体形vtr
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
JP2919890B2
(ja)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
CA2023779A1
(fr)
|
1989-08-23 |
1991-02-24 |
Margaret D. Moore |
Composes et methodes pour la detection et le traitement des infections a virus epstein-barr et des troubles de l'immunite
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5256643A
(en)
|
1990-05-29 |
1993-10-26 |
The Government Of The United States |
Human cripto protein
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
WO1992007574A1
(fr)
|
1990-10-25 |
1992-05-14 |
Tanox Biosystems, Inc. |
Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1992017497A1
(fr)
|
1991-03-29 |
1992-10-15 |
Genentech, Inc. |
Receptor humain pf4a et leur utilisation
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
JP3050424B2
(ja)
|
1991-07-12 |
2000-06-12 |
塩野義製薬株式会社 |
ヒトエンドセリンリセプター
|
US5264557A
(en)
|
1991-08-23 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Polypeptide of a human cripto-related gene, CR-3
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(fr)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions induisant la destruction de cellules infectees par l'hiv
|
US6153408A
(en)
|
1991-11-15 |
2000-11-28 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
US5976551A
(en)
|
1991-11-15 |
1999-11-02 |
Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and method of using the determinant
|
EP1997894B1
(fr)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Protéine de liaison biosynthétique pour un marqueur du cancer
|
DE69231123T2
(de)
|
1992-03-25 |
2001-02-15 |
Immunogen Inc |
Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
IL107366A
(en)
|
1992-10-23 |
2003-03-12 |
Chugai Pharmaceutical Co Ltd |
Genes coding for megakaryocyte potentiator
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5644033A
(en)
|
1992-12-22 |
1997-07-01 |
Health Research, Inc. |
Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
CA2163345A1
(fr)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Anticorps
|
US5773223A
(en)
|
1993-09-02 |
1998-06-30 |
Chiron Corporation |
Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
|
ES2233928T3
(es)
|
1993-10-01 |
2005-06-16 |
Teikoku Hormone Mfg. Co., Ltd. |
Derivados de dolastatina.
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5750370A
(en)
|
1995-06-06 |
1998-05-12 |
Human Genome Sciences, Inc. |
Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
US20020193567A1
(en)
|
1995-08-11 |
2002-12-19 |
Genetics Institute, Inc. |
Secreted proteins and polynucleotides encoding them
|
JP3646191B2
(ja)
|
1996-03-19 |
2005-05-11 |
大塚製薬株式会社 |
ヒト遺伝子
|
SK157498A3
(en)
|
1996-05-17 |
1999-10-08 |
Schering Corp |
Isolated and recombinant nucleic acid, bas-1 protein or peptide thereof, and agent, antibody, expression vector, host cell and method of their use
|
GB2315067B
(en)
|
1996-07-11 |
2000-02-16 |
Pharmacia Spa |
Morpholinyl anthracycline derivatives
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
US7033827B2
(en)
|
1997-02-25 |
2006-04-25 |
Corixa Corporation |
Prostate-specific polynucleotide compositions
|
US20030185830A1
(en)
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6261791B1
(en)
|
1997-03-10 |
2001-07-17 |
The Regents Of The University Of California |
Method for diagnosing cancer using specific PSCA antibodies
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
JP4404381B2
(ja)
|
1997-03-10 |
2010-01-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Psca:前立腺幹細胞抗原
|
US6555339B1
(en)
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
US6319688B1
(en)
|
1997-04-28 |
2001-11-20 |
Smithkline Beecham Corporation |
Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
|
ES2246069T3
(es)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
|
WO1998051824A1
(fr)
|
1997-05-15 |
1998-11-19 |
Abbott Laboratories |
Reactifs et procedes utiles au depistage de maladies du tractus urinaire
|
US6890749B2
(en)
|
1997-05-15 |
2005-05-10 |
Abbott Laboratories |
Reagents and methods useful for detecting diseases of the prostate
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
US20030060612A1
(en)
|
1997-10-28 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20020034749A1
(en)
|
1997-11-18 |
2002-03-21 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
US6110695A
(en)
|
1997-12-02 |
2000-08-29 |
The Regents Of The University Of California |
Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
WO1999046284A2
(fr)
|
1998-03-13 |
1999-09-16 |
The Burnham Institute |
Molecules se logeant dans divers organes ou tissus
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
AU4078599A
(en)
|
1998-05-13 |
1999-11-29 |
Epimmune, Inc. |
Expression vectors for stimulating an immune response and methods of using the same
|
US20030064397A1
(en)
|
1998-05-22 |
2003-04-03 |
Incyte Genomics, Inc. |
Transmembrane protein differentially expressed in prostate and lung tumors
|
US20020187472A1
(en)
|
2001-03-09 |
2002-12-12 |
Preeti Lal |
Steap-related protein
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
EP1413582B1
(fr)
|
1998-08-27 |
2006-03-15 |
Spirogen Limited |
Pyrrolobenzodiazépines dimériques
|
WO2000012130A1
(fr)
|
1998-08-27 |
2000-03-09 |
Smithkline Beecham Corporation |
Agonistes et antagonistes de rp105
|
JP4689781B2
(ja)
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
US6946261B1
(en)
|
1998-11-20 |
2005-09-20 |
Migenix Inc. |
Efficient methods for producing anti-microbial cationic peptides in host cells
|
WO2001057188A2
(fr)
|
2000-02-03 |
2001-08-09 |
Hyseq, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US6962980B2
(en)
|
1999-09-24 |
2005-11-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6468546B1
(en)
|
1998-12-17 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of ovarian cancer
|
US6858710B2
(en)
|
1998-12-17 |
2005-02-22 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030091580A1
(en)
|
2001-06-18 |
2003-05-15 |
Mitcham Jennifer L. |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030190669A1
(en)
|
1998-12-30 |
2003-10-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
JP2002536966A
(ja)
|
1998-12-30 |
2002-11-05 |
ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド |
カルシウムチャネルファミリーの特徴付け
|
JP2003512019A
(ja)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
変化したエフェクター機能を有するポリペプチド変異体
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1147190B1
(fr)
|
1999-01-29 |
2010-07-14 |
Corixa Corporation |
Proteines de fusion her-2/neu
|
GB9905124D0
(en)
|
1999-03-05 |
1999-04-28 |
Smithkline Beecham Biolog |
Novel compounds
|
AU3395900A
(en)
|
1999-03-12 |
2000-10-04 |
Human Genome Sciences, Inc. |
Human lung cancer associated gene sequences and polypeptides
|
US7312303B2
(en)
|
1999-05-11 |
2007-12-25 |
Genentech, Inc. |
Anti-PRO4980 antibodies
|
AU4952600A
(en)
|
1999-06-03 |
2000-12-28 |
Takeda Chemical Industries Ltd. |
Screening method with the use of cd100
|
BRPI0017590B8
(pt)
|
1999-06-25 |
2021-05-25 |
Genentech Inc |
conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
|
US7589172B2
(en)
|
1999-07-20 |
2009-09-15 |
Genentech, Inc. |
PRO256 polypeptides
|
US7297770B2
(en)
|
1999-08-10 |
2007-11-20 |
Genentech, Inc. |
PRO6496 polypeptides
|
US7294696B2
(en)
|
1999-08-17 |
2007-11-13 |
Genentech Inc. |
PRO7168 polypeptides
|
AU7573000A
(en)
|
1999-09-01 |
2001-03-26 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030129192A1
(en)
|
1999-09-10 |
2003-07-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030232056A1
(en)
|
1999-09-10 |
2003-12-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030206918A1
(en)
|
1999-09-10 |
2003-11-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6750054B2
(en)
|
2000-05-18 |
2004-06-15 |
Lexicon Genetics Incorporated |
Human semaphorin homologs and polynucleotides encoding the same
|
CA2387108A1
(fr)
|
1999-10-29 |
2001-06-07 |
Genentech, Inc. |
Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
|
ES2586850T3
(es)
|
1999-11-29 |
2016-10-19 |
The Trustees Of Columbia University In The City Of New York |
Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
|
EP1248800A2
(fr)
|
1999-11-30 |
2002-10-16 |
Corixa Corporation |
Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
|
AU2087401A
(en)
|
1999-12-10 |
2001-06-18 |
Epimmune, Inc. |
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
WO2001044463A1
(fr)
|
1999-12-15 |
2001-06-21 |
Genentech, Inc. |
Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
|
DK1246846T3
(da)
|
1999-12-23 |
2008-12-08 |
Zymogenetics Inc |
Oplöselig interleukin-20-receptor
|
JP2003535037A
(ja)
|
1999-12-23 |
2003-11-25 |
ザイモジェネティクス,インコーポレイティド |
炎症を治療する方法
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
NZ502058A
(en)
|
1999-12-23 |
2003-11-28 |
Ovita Ltd |
Isolated mutated nucleic acid molecule for regulation of ovulation rate
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
US7294695B2
(en)
|
2000-01-20 |
2007-11-13 |
Genentech, Inc. |
PRO10268 polypeptides
|
US20030224379A1
(en)
|
2000-01-21 |
2003-12-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
EP1252294A2
(fr)
|
2000-01-21 |
2002-10-30 |
Corixa Corporation |
Composes et procedes de prevention et de traitement de tumeurs malignes associes a her-2/neu
|
US20020142377A1
(en)
|
2000-02-22 |
2002-10-03 |
Glucksmann Maria Alexandra |
18607, a novel human calcium channel
|
US20030219806A1
(en)
|
2000-02-22 |
2003-11-27 |
Millennium Pharmaceuticals, Inc. |
Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040005561A1
(en)
|
2000-03-01 |
2004-01-08 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2001245280A1
(en)
|
2000-03-07 |
2001-09-17 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
AU4941101A
(en)
|
2000-03-24 |
2001-10-08 |
Fahri Saatcioglu |
Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
|
WO2004043361A2
(fr)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions et procedes de traitement des maladies liees aux cellules k naturelles
|
JP2003530325A
(ja)
|
2000-03-31 |
2003-10-14 |
イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター/リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
|
WO2001075177A2
(fr)
|
2000-04-03 |
2001-10-11 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Marqueurs tumoraux pour le cancer des ovaires
|
JP2003532057A
(ja)
|
2000-04-07 |
2003-10-28 |
アリーナ・フアーマシユーチカルズ・インコーポレーテツド |
非内因性の、構成的に活性化される既知gタンパク質−共役受容体
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
US20030119115A1
(en)
|
2000-05-17 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO2001090304A2
(fr)
|
2000-05-19 |
2001-11-29 |
Human Genome Sciences, Inc. |
Acides nucleiques, proteines et anticorps
|
WO2001094641A2
(fr)
|
2000-06-09 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Nouvelles cibles geniques et ligands se fixant a celles-ci pour le traitement et le diagnostic de carcinomes ovariens
|
EP1297130A2
(fr)
|
2000-06-16 |
2003-04-02 |
Incyte Genomics, Inc. |
Recepteur couple a la proteine g
|
EP1301524A1
(fr)
|
2000-06-30 |
2003-04-16 |
Human Genome Sciences, Inc. |
Polynucl otides du type b7, polypeptides et anticorps en rapport
|
AU2001273151A1
(en)
|
2000-06-30 |
2002-01-14 |
Incyte Genomics, Inc. |
Human extracellular matrix and cell adhesion polypeptides
|
CA2413262A1
(fr)
|
2000-06-30 |
2002-01-10 |
Amgen, Inc. |
Molecules de type b7 et utilisation de ces molecules
|
AU2002214531A1
(en)
|
2000-07-03 |
2002-01-30 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040044179A1
(en)
|
2000-07-25 |
2004-03-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU2001283507A1
(en)
|
2000-07-27 |
2002-02-13 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
ATE396266T1
(de)
|
2000-07-28 |
2008-06-15 |
Ulrich Wissenbach |
Trp8 krebsmarker
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
EP1366153A2
(fr)
|
2000-08-14 |
2003-12-03 |
Corixa Corporation |
Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
|
WO2002013847A2
(fr)
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
|
EP1311674A2
(fr)
|
2000-08-24 |
2003-05-21 |
Genentech, Inc. |
Compositions et procedes de diagnostic et traitement de tumeurs
|
GB0020953D0
(en)
|
2000-08-24 |
2000-10-11 |
Smithkline Beecham Biolog |
Vaccine
|
US8314060B2
(en)
|
2000-09-05 |
2012-11-20 |
Biosight Ltd. |
Peptide conjugated anti-cancer prodrugs
|
EP1346040A2
(fr)
|
2000-09-11 |
2003-09-24 |
Nuvelo, Inc. |
Noveaux acides nucleiques et polypeptides
|
DE60121808T2
(de)
|
2000-09-15 |
2007-03-29 |
Zymogenetics, Inc., Seattle |
Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
|
US6613567B1
(en)
|
2000-09-15 |
2003-09-02 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of Her-2 expression
|
US20030119121A1
(en)
|
2000-09-15 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
JP2004524810A
(ja)
|
2000-09-18 |
2004-08-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto変異体およびその使用
|
CA2425569A1
(fr)
|
2000-10-13 |
2002-04-18 |
Eos Biotechnology, Inc. |
Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DK1407017T3
(en)
|
2000-11-07 |
2009-09-21 |
Zymogenetics Inc |
Human receptor for tumor nekrose faktor
|
US20020150573A1
(en)
|
2000-11-10 |
2002-10-17 |
The Rockefeller University |
Anti-Igalpha-Igbeta antibody for lymphoma therapy
|
CN101940189A
(zh)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
WO2002061087A2
(fr)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
|
US20020159986A1
(en)
|
2001-01-12 |
2002-10-31 |
John Langenfeld |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
US20030119126A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030119125A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
JP2005503760A
(ja)
|
2001-01-24 |
2005-02-10 |
プロテイン デザイン ラブス, インコーポレイテッド |
乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
|
US20030073144A1
(en)
|
2001-01-30 |
2003-04-17 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of pancreatic cancer
|
US20040170994A1
(en)
|
2001-02-12 |
2004-09-02 |
Callen David Frederick |
DNA sequences for human tumour suppressor genes
|
WO2002071928A2
(fr)
|
2001-03-14 |
2002-09-19 |
Millennium Pharmaceuticals, Inc. |
Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
|
EP1243276A1
(fr)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Prodrogues activables à séparateurs allongés et multiples
|
WO2002078524A2
(fr)
|
2001-03-28 |
2002-10-10 |
Zycos Inc. |
Determination de profils translationnels
|
WO2003008537A2
(fr)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Sequences d'epitope
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
WO2002083866A2
(fr)
|
2001-04-17 |
2002-10-24 |
The Board Of Trustees Of The University Of Arkansas |
Sequences repetees du gene ca125 et leurs utilisations dans des interventions diagnostiques et therapeutiques
|
WO2002086443A2
(fr)
|
2001-04-18 |
2002-10-31 |
Protein Design Labs, Inc |
Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
|
SI1390389T1
(sl)
|
2001-04-26 |
2009-06-30 |
Biogen Idec Inc |
Protitelesa, ki blokirajo cripto in uporabe le-teh
|
AU2002334799B2
(en)
|
2001-04-26 |
2009-05-07 |
Biogen Ma Inc. |
Cripto-specific antibodies
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
EP1515982A4
(fr)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
|
WO2002092836A2
(fr)
|
2001-05-11 |
2002-11-21 |
Sloan-Kettering Institute For Cancer Research |
Sequence nucleotidique codant un antigene ovarien ca125 et ses utilisations
|
KR20040030628A
(ko)
|
2001-05-24 |
2004-04-09 |
지모제넥틱스, 인코포레이티드 |
Taci-면역글로불린 융합 단백질
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US7157558B2
(en)
|
2001-06-01 |
2007-01-02 |
Genentech, Inc. |
Polypeptide encoded by a polynucleotide overexpresses in tumors
|
WO2002098358A2
(fr)
|
2001-06-04 |
2002-12-12 |
Eos Biotechnology, Inc. |
Procedes de diagnostic et de traitement du cancer prostatique androgene-dependant, cancer prostatique subissant un retrait d'androgenes et cancer prostatique androgene-independant
|
JP2005518185A
(ja)
|
2001-06-04 |
2005-06-23 |
キュラジェン コーポレイション |
新規タンパク質およびそれをコード化する核酸
|
AU2002310256A1
(en)
|
2001-06-05 |
2002-12-16 |
Exelixis Inc. |
Ppp2cs as modifiers of the p53 pathway and methods of use
|
AU2002320264B2
(en)
|
2001-06-05 |
2008-05-01 |
Exelixis, Inc. |
GFATs as modifiers of the p53 pathway and methods of use
|
US7235358B2
(en)
|
2001-06-08 |
2007-06-26 |
Expression Diagnostics, Inc. |
Methods and compositions for diagnosing and monitoring transplant rejection
|
WO2002101075A2
(fr)
|
2001-06-13 |
2002-12-19 |
Millennium Pharmaceuticals, Inc. |
Identification, evaluation, prevention et traitement du cancer du col de l'uterus : nouveaux genes, nouvelles compositions, nouvelles trousses et nouvelles methodes
|
US7189507B2
(en)
|
2001-06-18 |
2007-03-13 |
Pdl Biopharma, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
EP1517998A2
(fr)
|
2001-06-18 |
2005-03-30 |
EOS Biotechnology, Inc. |
Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
|
US7705120B2
(en)
|
2001-06-21 |
2010-04-27 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
WO2003002717A2
(fr)
|
2001-06-28 |
2003-01-09 |
Schering Corporation |
Activite biologique de ak155
|
WO2003004529A2
(fr)
|
2001-07-02 |
2003-01-16 |
Licentia Ltd. |
Materiaux de recepteur ephrine-tie et leurs procedes
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
WO2003003984A2
(fr)
|
2001-07-05 |
2003-01-16 |
Curagen Corporation |
Nouvelles proteines et nouveaux acides nucleiques codant ces proteines
|
WO2003055439A2
(fr)
|
2001-07-18 |
2003-07-10 |
The Regents Of The University Of California |
Antigene cible her2/neu et son utilisation pour stimuler une reponse immunitaire
|
AU2002337657A1
(en)
|
2001-07-25 |
2003-02-17 |
Millennium Pharmaceuticals, Inc. |
Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
|
EA200601861A1
(ru)
|
2001-08-03 |
2007-02-27 |
Дженентек, Инк. |
ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
|
US20070015145A1
(en)
|
2001-08-14 |
2007-01-18 |
Clifford Woolf |
Nucleic acid and amino acid sequences involved in pain
|
US20030092013A1
(en)
|
2001-08-16 |
2003-05-15 |
Vitivity, Inc. |
Diagnosis and treatment of vascular disease
|
AU2002313559A1
(en)
|
2001-08-23 |
2003-03-10 |
Oxford Biomedica (Uk) Limited |
Genes
|
AU2002357643A1
(en)
|
2001-08-29 |
2003-04-14 |
Vanderbilt University |
The human mob-5 (il-24) receptors and uses thereof
|
US20030124579A1
(en)
|
2001-09-05 |
2003-07-03 |
Eos Biotechnology, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
AU2002336446B2
(en)
|
2001-09-06 |
2008-03-06 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
|
JP2005518782A
(ja)
|
2001-09-17 |
2005-06-30 |
プロテイン デザイン ラブス, インコーポレイテッド |
ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
|
EP1487877B1
(fr)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Compositions et procedes pour le diagnostic de tumeurs
|
IL160933A0
(en)
|
2001-09-18 |
2004-08-31 |
Proteologics Inc |
Methods and compositions for treating ?cap associated diseases
|
CA2460621A1
(fr)
|
2001-09-19 |
2003-03-27 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US20030077644A1
(en)
|
2001-09-28 |
2003-04-24 |
Bing Yang |
Diagnosis and treatment of diseases caused by mutations in CD72
|
WO2003029277A2
(fr)
|
2001-10-03 |
2003-04-10 |
Rigel Pharmaceuticals, Inc. |
Modulateurs de l'activation et de la migration des lymphocytes
|
US20040249144A1
(en)
|
2001-10-03 |
2004-12-09 |
Zairen Sun |
Regulated breast cancer genes
|
US20030228319A1
(en)
|
2002-04-16 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2002351505B2
(en)
|
2001-10-19 |
2008-04-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7825089B2
(en)
|
2001-10-24 |
2010-11-02 |
National Jewish Health |
Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
|
MXPA04003697A
(es)
|
2001-10-31 |
2005-04-08 |
Alcon Inc |
Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
|
WO2003042661A2
(fr)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
|
US20030232350A1
(en)
|
2001-11-13 |
2003-12-18 |
Eos Biotechnology, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
WO2003045422A1
(fr)
|
2001-11-29 |
2003-06-05 |
Genset S.A. |
Agonistes et antagonistes de la prolixine pour le traitement des troubles metaboliques
|
AU2002349784A1
(en)
|
2001-12-03 |
2003-06-17 |
Asahi Kasei Pharma Corporation |
Nf-kappab activating genes
|
WO2003054152A2
(fr)
|
2001-12-10 |
2003-07-03 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
US20030134790A1
(en)
|
2002-01-11 |
2003-07-17 |
University Of Medicine And Dentistry Of New Jersey |
Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
EP1485130A4
(fr)
|
2002-02-21 |
2006-11-22 |
Univ Duke |
Reactifs et methodes therapeutiques de maladies auto-immunes
|
CA2476518A1
(fr)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions et methodes de traitement de maladies relatives au systeme immunitaire
|
US20030232013A1
(en)
|
2002-02-22 |
2003-12-18 |
Gary Sieckman |
Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
|
AU2003224638A1
(en)
|
2002-03-01 |
2003-09-16 |
Exelixis, Inc. |
PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
|
WO2003097803A2
(fr)
|
2002-05-15 |
2003-11-27 |
Avalon Pharmaceuticals |
Gene lie au cancer utilise comme cible pour la chimiotherapie
|
EP2258712A3
(fr)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
|
WO2004000997A2
(fr)
|
2002-03-19 |
2003-12-31 |
Curagen Corporation |
Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
|
JP2005534286A
(ja)
|
2002-03-21 |
2005-11-17 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
キナーゼインヒビターの同定
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
EP1490085A2
(fr)
|
2002-03-25 |
2004-12-29 |
Uab Research Foundation |
Homologues des recepteurs de fc, reactifs associes et leurs utilisations
|
WO2003083074A2
(fr)
|
2002-03-28 |
2003-10-09 |
Idec Pharmaceuticals Corporation |
Nouvelles cibles geniques et ligands se liant a celles-ci pour le traitement et le diagnostic de carcinomes du colon
|
US20030194704A1
(en)
|
2002-04-03 |
2003-10-16 |
Penn Sharron Gaynor |
Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
|
BR0308953A
(pt)
|
2002-04-05 |
2006-03-14 |
Agensys Inc |
composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
|
WO2003087768A2
(fr)
|
2002-04-12 |
2003-10-23 |
Mitokor |
Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
|
US20030224467A1
(en)
|
2002-04-17 |
2003-12-04 |
Osborne C. Kent |
AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
|
AU2003228869A1
(en)
|
2002-05-03 |
2003-11-17 |
Incyte Corporation |
Transporters and ion channels
|
AU2003234624B8
(en)
|
2002-05-17 |
2009-03-12 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
AU2003232453A1
(en)
|
2002-05-30 |
2003-12-19 |
David K. Bol |
Human solute carrier family 7 member 11 (hslc7a11)
|
AU2003239966B9
(en)
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003240495A1
(en)
|
2002-06-04 |
2003-12-19 |
Incyte Corporation |
Diagnostics markers for lung cancer
|
EP1575492A4
(fr)
|
2002-06-04 |
2007-05-09 |
Avalon Pharmaceuticals |
Gene lie au cancer comme cible de chimiotherapie
|
AU2003242633A1
(en)
|
2002-06-06 |
2003-12-22 |
Molecular Engines Laboratories |
Dudulin genes, non-human animal model: uses in human hematological disease
|
CA2488404C
(fr)
|
2002-06-06 |
2012-11-27 |
Oncotherapy Science, Inc. |
Genes et polypeptides en rapport avec les cancers du colon chez l'homme
|
AU2003249691A1
(en)
|
2002-06-07 |
2003-12-22 |
Avalon Pharmaceuticals, Inc |
Cancer-linked gene as target for chemotherapy
|
AU2003245441A1
(en)
|
2002-06-12 |
2003-12-31 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
US20040249130A1
(en)
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
CA2487809A1
(fr)
|
2002-06-18 |
2003-12-24 |
Archemix Corp. |
Molecules toxine-aptamere et procedes d'utilisation correspondants
|
AU2003245615A1
(en)
|
2002-06-20 |
2004-01-06 |
The Regents Of The University Of California |
Compositions and methods for modulating lymphocyte activity
|
EP1534331B1
(fr)
|
2002-06-21 |
2014-10-29 |
Johns Hopkins University School of Medicine |
Marqueurs de l'endothelium tumoral associe a une membrane
|
AU2003281515A1
(en)
|
2002-07-19 |
2004-02-09 |
Cellzome Ag |
Protein complexes of cellular networks underlying the development of cancer and other diseases
|
BR0313033A
(pt)
|
2002-07-25 |
2007-07-10 |
Genentech Inc |
anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
|
ES2556641T3
(es)
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
AU2003251471A1
(en)
|
2002-08-06 |
2004-02-25 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
|
JP2004121218A
(ja)
|
2002-08-06 |
2004-04-22 |
Jenokkusu Soyaku Kenkyusho:Kk |
気管支喘息または慢性閉塞性肺疾患の検査方法
|
AU2003259163B2
(en)
|
2002-08-16 |
2008-07-03 |
Immunogen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
CA2495389A1
(fr)
|
2002-08-19 |
2004-02-26 |
Genentech, Inc. |
Compositions et methodes de diagnostic et de traitement des tumeurs
|
JP2006515742A
(ja)
|
2002-08-27 |
2006-06-08 |
ブリストル−マイヤーズ スクイブ カンパニー |
乳癌細胞でのプロテインチロシンキナーゼおよび/またはプロテインチロシンキナーゼ経路と相互作用および/またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定
|
WO2004020595A2
(fr)
|
2002-08-29 |
2004-03-11 |
Five Prime Therapeutics, Inc. |
Nouveaux polypeptides humains codes par des polynucleotides
|
AU2002951346A0
(en)
|
2002-09-05 |
2002-09-26 |
Garvan Institute Of Medical Research |
Diagnosis of ovarian cancer
|
JP2005537800A
(ja)
|
2002-09-06 |
2005-12-15 |
マンカインド コーポレイション |
エピトープ配列
|
US20060134109A1
(en)
|
2002-09-09 |
2006-06-22 |
Nura Inc. |
G protein coupled receptors and uses thereof
|
JP2004113151A
(ja)
|
2002-09-27 |
2004-04-15 |
Sankyo Co Ltd |
癌遺伝子及びその用途
|
AU2003278002A1
(en)
|
2002-10-03 |
2004-04-23 |
Mcgill Univeristy |
Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
|
CA2501131A1
(fr)
|
2002-10-04 |
2004-04-22 |
Van Andel Research Institute |
Sous classification moleculaire de tumeurs renales et decouverte de nouveaux marqueurs diagnostiques
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
NZ538996A
(en)
|
2002-10-31 |
2008-04-30 |
Genentech Inc |
Methods and compositions for increasing antibody production
|
WO2004044178A2
(fr)
|
2002-11-13 |
2004-05-27 |
Genentech, Inc. |
Procedes et compositions pour diagnostiquer une dysplasie
|
CA2505601C
(fr)
|
2002-11-15 |
2014-10-28 |
Musc Foundation For Research Development |
Modulateurs de complement cibles sur le recepteur 2 de complement
|
WO2004045553A2
(fr)
|
2002-11-15 |
2004-06-03 |
The Board Of Trustees Of The University Of Arkansas |
Gene ca125 et utilisation de celui-ci aux fins d'interventions diagnostiques et therapeutiques
|
AU2003297300A1
(en)
|
2002-11-20 |
2004-06-15 |
Biogen Idec Inc. |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
|
EP2410332A1
(fr)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Méthode d'identification de modulateurs purinergiques du système olfactif
|
WO2004048938A2
(fr)
|
2002-11-26 |
2004-06-10 |
Protein Design Labs, Inc. |
Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
|
WO2004053079A2
(fr)
|
2002-12-06 |
2004-06-24 |
Diadexus, Inc. |
Compositions, variants d'epissage et methodes concernant des genes et des proteines specifiques des ovaires
|
JP2004198419A
(ja)
|
2002-12-13 |
2004-07-15 |
Bayer Healthcare Llc |
Timp1を用いた検出方法
|
PL212899B1
(pl)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
|
CA2510315C
(fr)
|
2002-12-20 |
2014-01-28 |
Protein Design Labs, Inc. |
Anticorps anti-gpr64 et utilisations
|
US20050249671A9
(en)
|
2002-12-23 |
2005-11-10 |
David Parmelee |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
JP2007520995A
(ja)
|
2003-01-08 |
2007-08-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
|
US20050227301A1
(en)
|
2003-01-10 |
2005-10-13 |
Polgen |
Cell cycle progression proteins
|
WO2004063355A2
(fr)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
|
EP1583820A4
(fr)
|
2003-01-14 |
2007-07-18 |
Bristol Myers Squibb Co |
Polynucleotides et polypeptides associes a la voie nf-kb
|
WO2004065576A2
(fr)
|
2003-01-15 |
2004-08-05 |
Millennium Pharmaceuticals, Inc. |
Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,
|
EP1585767A2
(fr)
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Banques de phages anticorps synthetiques
|
US7575893B2
(en)
|
2003-01-23 |
2009-08-18 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
EP1594893A2
(fr)
|
2003-02-14 |
2005-11-16 |
Sagres Discovery, Inc. |
Cibles therapeutiques pour le cancer
|
US20030224411A1
(en)
|
2003-03-13 |
2003-12-04 |
Stanton Lawrence W. |
Genes that are up- or down-regulated during differentiation of human embryonic stem cells
|
EP1608664B1
(fr)
|
2003-03-31 |
2009-01-28 |
Council of Scientific and Industrial Research |
Pyrrolo[2,1-c][1,4]benzodiazepines non-reticulees comme agents anticancereux potentiels et leur procede de preparation
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
CA2543318C
(fr)
|
2003-10-22 |
2013-01-08 |
B. Rao Vishnuvajjala |
Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
JP5166861B2
(ja)
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
ピロロベンゾジアゼピン
|
JP5128935B2
(ja)
|
2004-03-31 |
2013-01-23 |
ジェネンテック, インコーポレイテッド |
ヒト化抗TGF−β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP2360186B1
(fr)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anticorps dirigés contre la sélectine P
|
NZ579482A
(en)
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
RU2423382C1
(ru)
|
2005-06-20 |
2011-07-10 |
Дженентек, Инк. |
Композиции и способы диагностики и лечения опухоли
|
US20070060534A1
(en)
|
2005-06-30 |
2007-03-15 |
Threshold Pharmaceuticals, Inc. |
Anthracycline analogs
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP1957531B1
(fr)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
|
EP1973951A2
(fr)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Polypeptides de liaison avec des sequences de diversite limitees
|
EP1813614B1
(fr)
|
2006-01-25 |
2011-10-05 |
Sanofi |
Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine
|
TW200812616A
(en)
|
2006-05-09 |
2008-03-16 |
Genentech Inc |
Binding polypeptides with optimized scaffolds
|
WO2007147901A1
(fr)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production d'anticorps bispécifiques
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
PT2019104E
(pt)
|
2007-07-19 |
2013-12-03 |
Sanofi Sa |
Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
ES2547552T3
(es)
|
2008-02-01 |
2015-10-07 |
Genentech, Inc. |
Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
|
EP2303332B1
(fr)
|
2008-07-15 |
2014-12-31 |
Genentech, Inc. |
Conjugués de dérivés d anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
|
SG2014009138A
(en)
|
2009-02-05 |
2014-03-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
PT3192529T
(pt)
|
2009-04-08 |
2020-04-16 |
Deutsches Krebsforsch |
Componentes terapêuticos de ligação à superfície celular armados com amatoxina destinados à terapia de tumores
|
CA2793890C
(fr)
|
2010-04-15 |
2017-08-15 |
Spirogen Developments Sarl |
Pyrrolobenzodiazepines et conjugues de celles-ci
|
JP6048972B2
(ja)
|
2010-04-23 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
ヘテロ多量体タンパク質の産生
|
WO2011157713A2
(fr)
|
2010-06-14 |
2011-12-22 |
F. Hoffmann-La Roche Ag |
Peptides pénétrant dans les cellules et leurs utilisations
|
EP2436398B1
(fr)
|
2010-09-30 |
2013-01-23 |
Heidelberg Pharma GmbH |
Conjugués d'amatoxine avec liens améliorés
|
CA2816426A1
(fr)
|
2010-11-17 |
2012-06-07 |
Genentech, Inc. |
Conjugues d'anticorps alaninyl-maytansinol
|
BR112013013127B1
(pt)
|
2010-12-02 |
2021-06-22 |
Nerviano Medical Sciences S.R.L. |
Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos
|
EP2497499A1
(fr)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Conjugués d'amatoxine avec liens améliorés
|
DK2691417T3
(en)
|
2011-03-29 |
2018-11-19 |
Roche Glycart Ag |
ANTIBODY FC VARIANTS
|
EP2750713B1
(fr)
*
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazépines et conjugués associés
|
BR112015000441A2
(pt)
*
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
WO2014043403A1
(fr)
|
2012-09-12 |
2014-03-20 |
Agensys, Inc. |
Dérivés d'amatoxine et conjugués à base de ceux-ci, à perméabilité cellulaire, en tant qu'inhibiteurs de l'arn polymérase
|
ES2656298T3
(es)
*
|
2012-11-05 |
2018-02-26 |
Pfizer Inc. |
Análogos de ayustoestatina
|
EP2774624A1
(fr)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Dérivés d'amatoxine
|
EP2968596B1
(fr)
|
2013-03-13 |
2019-03-06 |
Medimmune Limited |
Pyrrolobenzodiazépines et leurs conjugués
|
US20140349944A1
(en)
|
2013-05-23 |
2014-11-27 |
Musc Foundation For Research Development |
Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
|
WO2015023355A1
(fr)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
|
BR112016013258A2
(pt)
*
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
AU2014364927A1
(en)
|
2013-12-16 |
2016-07-07 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
WO2015110935A1
(fr)
*
|
2014-01-27 |
2015-07-30 |
Pfizer Inc. |
Agents cytotoxiques bifonctionnels
|
WO2016040825A1
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
|
MX2017003523A
(es)
*
|
2014-09-17 |
2017-11-08 |
Genentech Inc |
Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
|
MA43345A
(fr)
*
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|